Replimune Group (FRA:7R8) Volatility: 314.87% (As of Jul. 11, 2026)


FRA:7R8 Replimune Group Inc FRA:7R8
32 GF Score
Price €9.22
! 4 Warning Signs
View Full Analysis

What is Replimune Group Volatility?

Replimune Group FRA:7R8 -3.56% 32 Volatility is 314.87% as of Jul. 11, 2026. GuruFocus rates FRA:7R8 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-07-11), Replimune Group's Volatility is 314.87%.

Replimune Group  (FRA:7R8) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Replimune Group Volatility Related Terms

FRA:7R8 vs AVTX, KURA, SANA: Volatility Comparison

For the Biotechnology subindustry, Replimune Group's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Replimune Group Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Replimune Group's Volatility distribution charts can be found below:

* The bar in red indicates where Replimune Group's Volatility falls into.


FRA:7R8
32GF Score
Replimune Group Inc FRA:7R8
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Replimune Group  (FRA:7R8) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 314.87% mean?
Replimune Group (FRA:7R8) has a Volatility of 314.87% as of Jul. 11, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Replimune Group and its competitors.
Is Replimune Group's Volatility too high?
Replimune Group's current Volatility is 314.87%. Overall, Replimune Group has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's Volatility compare to AVTX and KURA?
Replimune Group's Volatility of 314.87% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Replimune Group and its competitors. Replimune Group's current Volatility is 314.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (FRA:7R8) has a current Volatility of 314.87%. The current Volatility is 314.87%. Replimune Group's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current Volatility is 314.87% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Replimune Group Business Description

Other Exchanges REPL:USA
Address 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
32GF Score

Get the complete analysis for FRA:7R8

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.22
Price